- abnormal spleen morphology / IMPC
- abnormal placenta morphology / IMPC
- persistence of hyaloid vascular system / IMPC
- embryonic growth retardation / IMPC
- small spleen / IMPC
- preweaning lethality, complete penetrance / IMPC
- abnormal eye morphology / IMPC
- abnormal ovary morphology / IMPC
- abnormal kidney morphology / IMPC
- abnormal testis morphology / IMPC
- edema / IMPC
- abnormal blood vessel morphology / IMPC
- microphthalmia / IMPC
- increased circulating calcium level / IMPC
- enlarged kidney / IMPC
- enlarged testis / IMPC
- anophthalmia / IMPC
- abnormal placenta vasculature / IMPC
C57BL/6-Tcf21tm(rtTA)/H
Status | Available to order |
EMMA ID | EM:15189 |
International strain name | C57BL/6-Tcf21tm(rtTA)/H |
Alternative name | TCF21-rtTA |
Strain type | Targeted Mutant Strains : Knock-in |
Allele/Transgene symbol | Tcf21-rtTA |
Gene/Transgene symbol | Tcf21 |
Information from provider
Provider | Christopher Switzer |
Provider affiliation | Queen Mary University of London |
Genetic information | Reverse Tet-off rtTA protein controlled by Tcf21 promoter (fibroblast-specific). A 9.1 kb region was first subcloned from a positively identified C57BL/6 fosmid clone (WI1-336E22) and used to build the targeting vector using homologous recombination-based techniques. The region is designed so that the long homology arm (LA) extends 6.2 kb upstream of the P2A-rtTA knock-in cassette and the short homology arm (SA) extends 2.3 kb downstream of the neo cassette. The P2A-rtTA cassette was inserted upstream of the TGA stop codon in exon 2 of the mouse Tcf21 gene. The FRT flanked neo selection cassette followed downstream of the 3’-UTR sequence. The targeting vector was confirmed by restriction analysis and sequencing after each modification step. The boundaries of the 2 homology arms were confirmed by sequencing with primers P6 and T73 that read through both sides of the backbone vector into the genomic sequences. The P2A-rtTA knock-in cassette was confirmed by sequencing with primers TCFC SQ1 and SQ2. IV-neo N3 and ineo N2 primers, reading from the selection cassette, confirmed the insertion of the neo cassette. The PTRE3G promoter has been used. |
Phenotypic information | Homozygous:No observable phenotypic differences.Heterozygous:No observable phenotypic differences. |
Breeding history | |
References | None available |
Homozygous fertile | yes |
Homozygous viable | yes |
Homozygous matings required | no |
Immunocompromised | no |
Information from EMMA
Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Disease and phenotype information
IMPC phenotypes (gene matching)
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).